ZyVersa Therapeutics, Inc. (ZVSA) Financial Ratios
6 years of historical data (2020–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
N/A
—
5yr avg: 0.12
30Y Low0.1·High0.1
ROE
↓
N/A
—
5yr avg: -32102.8%
30Y Low-177%·High-32%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ZVSA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
ZyVersa Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $1.2B | $799M | $1M | $877527 | $14M | — | — |
| Enterprise Value | $1.1B | $697M | $-354289 | $-2251491 | $8M | — | — |
| P/E Ratio → | -0.05 | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — |
| P/B Ratio | — | — | 0.14 | 0.08 | 0.14 | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ZVSA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
ZVSA Profitability
Margins and return-on-capital ratios measuring operating efficiency
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | — | — | -96099.4% | -177.0% | -32.1% | — | — |
| ROA | -13542.7% | -13542.7% | -44076.9% | -139.8% | -23.5% | -892.4% | -1850.0% |
| ROIC | — | — | -91789.9% | -21.2% | -22.9% | — | — |
| ROCE | — | — | -85841.8% | -23.6% | -28.3% | — | — |
ZVSA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $102M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 0.00 | 0.00 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -0.18 | -0.28 | -0.06 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -49.28 | -49.28 | -33908.17 | — | -33.77 | -8.84 | -23.56 |
Net cash position: cash ($102M) exceeds total debt ($0)
ZVSA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.03x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 0.33x to 0.03x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 0.03 | 0.03 | 0.15 | 0.33 | 0.78 | 0.06 | 0.04 |
| Quick Ratio | 0.03 | 0.03 | 0.15 | 0.33 | 0.78 | 0.06 | 0.04 |
| Cash Ratio | 0.01 | 0.01 | 0.14 | 0.31 | 0.72 | 0.02 | 0.02 |
| Asset Turnover | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — |
ZVSA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
ZyVersa Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 100.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 100.0% | 0.0% | — | — |
| Shares Outstanding | — | $6.0B | $1M | $97503 | $25948 | $46552 | $46552 |
Peer Comparison
Compare ZVSA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ZVSAYou | $1B | -0.0 | — | — | — | — | — | — | — |
 RCKT | $371M | -1.7 | — | — | — | — | -60.3% | -62.4% | — |
 PRAX | $10B | -25.6 | — | — | — | — | -45.8% | -65.0% | — |
 IMVT | $6B | -10.6 | — | — | — | — | -62.5% | — | — |
 VKTX | $4B | -9.9 | — | — | — | — | -47.3% | -44.4% | — |
 ALDX | $100M | -1.8 | — | — | — | — | -58.5% | -369.4% | — |
 ARQT | $3B | -165.9 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 RARE | $3B | -4.4 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 HALO | $8B | 27.0 | 8.9 | 12.7 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 KRYS | $9B | 46.2 | 52.7 | 49.4 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
| Healthcare Median | — | 21.7 | 14.0 | 18.1 | 64.1% | -4.8% | -32.9% | -10.8% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 6 years · Updated daily
See ZVSA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ZVSA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ZVSA vs RCKT
Side-by-side business, growth, and profitability comparison vs Rocket Pharmaceuticals, Inc..
Start ComparisonZVSA — Frequently Asked Questions
Quick answers to the most common questions about buying ZVSA stock.
What is ZyVersa Therapeutics, Inc.'s P/E ratio?
ZyVersa Therapeutics, Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Is ZVSA stock overvalued?
Based on historical data, ZyVersa Therapeutics, Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.